vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and LiveOne, Inc. (LVO). Click either name above to swap in a different company.

LiveOne, Inc. is the larger business by last-quarter revenue ($20.3M vs $19.6M, roughly 1.0× STANDARD BIOTOOLS INC.). LiveOne, Inc. runs the higher net margin — -20.1% vs -177.4%, a 157.3% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (-11.5% vs -31.2%). LiveOne, Inc. produced more free cash flow last quarter ($-2.9M vs $-23.1M). Over the past eight quarters, STANDARD BIOTOOLS INC.'s revenue compounded faster (-12.2% CAGR vs -19.0%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Live Nation Entertainment, Inc. is an American multinational entertainment company that was founded in 2010 following the merger of Live Nation and Ticketmaster. It continues to operate both brands as subsidiary companies, promoting and managing ticket sales for live entertainment internationally. It also owns and operates entertainment venues and manages the careers of music artists.

LAB vs LVO — Head-to-Head

Bigger by revenue
LVO
LVO
1.0× larger
LVO
$20.3M
$19.6M
LAB
Growing faster (revenue YoY)
LAB
LAB
+19.7% gap
LAB
-11.5%
-31.2%
LVO
Higher net margin
LVO
LVO
157.3% more per $
LVO
-20.1%
-177.4%
LAB
More free cash flow
LVO
LVO
$20.2M more FCF
LVO
$-2.9M
$-23.1M
LAB
Faster 2-yr revenue CAGR
LAB
LAB
Annualised
LAB
-12.2%
-19.0%
LVO

Income Statement — Q3 FY2025 vs Q3 FY2026

Metric
LAB
LAB
LVO
LVO
Revenue
$19.6M
$20.3M
Net Profit
$-34.7M
$-4.1M
Gross Margin
48.5%
18.8%
Operating Margin
-168.5%
-9.6%
Net Margin
-177.4%
-20.1%
Revenue YoY
-11.5%
-31.2%
Net Profit YoY
-28.8%
22.3%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
LVO
LVO
Q4 25
$20.3M
Q3 25
$19.6M
$18.8M
Q2 25
$21.8M
$19.2M
Q1 25
$40.8M
$19.3M
Q4 24
$29.4M
Q3 24
$22.1M
$32.6M
Q2 24
$22.5M
$33.1M
Q1 24
$45.5M
$30.9M
Net Profit
LAB
LAB
LVO
LVO
Q4 25
$-4.1M
Q3 25
$-34.7M
$-5.5M
Q2 25
$-33.5M
$-3.6M
Q1 25
$-26.0M
$-10.4M
Q4 24
$-5.2M
Q3 24
$-26.9M
$-1.9M
Q2 24
$-45.7M
$-1.2M
Q1 24
$-32.2M
$-2.3M
Gross Margin
LAB
LAB
LVO
LVO
Q4 25
18.8%
Q3 25
48.5%
13.8%
Q2 25
48.8%
12.4%
Q1 25
48.4%
30.8%
Q4 24
24.3%
Q3 24
54.9%
24.8%
Q2 24
46.1%
24.2%
Q1 24
53.1%
25.5%
Operating Margin
LAB
LAB
LVO
LVO
Q4 25
-9.6%
Q3 25
-168.5%
-24.4%
Q2 25
-118.1%
-21.0%
Q1 25
-80.8%
-55.8%
Q4 24
-17.4%
Q3 24
-120.9%
-4.3%
Q2 24
-134.5%
-2.4%
Q1 24
-132.2%
-3.7%
Net Margin
LAB
LAB
LVO
LVO
Q4 25
-20.1%
Q3 25
-177.4%
-29.5%
Q2 25
-153.7%
-18.7%
Q1 25
-63.8%
-54.2%
Q4 24
-17.8%
Q3 24
-122.0%
-5.7%
Q2 24
-203.3%
-3.5%
Q1 24
-70.6%
-7.4%
EPS (diluted)
LAB
LAB
LVO
LVO
Q4 25
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
Q4 24
Q3 24
$-0.07
Q2 24
$-0.12
Q1 24
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
LVO
LVO
Cash + ST InvestmentsLiquidity on hand
$129.4M
$8.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$-19.0M
Total Assets
$539.6M
$52.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
LVO
LVO
Q4 25
$8.6M
Q3 25
$129.4M
$11.7M
Q2 25
$158.6M
$11.9M
Q1 25
$150.9M
$4.1M
Q4 24
$10.9M
Q3 24
$210.6M
$11.1M
Q2 24
$269.8M
$6.2M
Q1 24
$287.1M
$7.0M
Total Debt
LAB
LAB
LVO
LVO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
LVO
LVO
Q4 25
$-19.0M
Q3 25
$399.7M
$-16.2M
Q2 25
$424.5M
$-20.8M
Q1 25
$454.6M
$-17.8M
Q4 24
$-8.4M
Q3 24
$489.3M
$-4.7M
Q2 24
$510.3M
$-3.8M
Q1 24
$577.3M
$-8.7M
Total Assets
LAB
LAB
LVO
LVO
Q4 25
$52.3M
Q3 25
$539.6M
$53.8M
Q2 25
$557.0M
$48.9M
Q1 25
$579.6M
$40.5M
Q4 24
$56.2M
Q3 24
$681.5M
$67.2M
Q2 24
$708.7M
$64.6M
Q1 24
$777.7M
$63.9M
Debt / Equity
LAB
LAB
LVO
LVO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
LVO
LVO
Operating Cash FlowLast quarter
$-22.2M
$-2.3M
Free Cash FlowOCF − Capex
$-23.1M
$-2.9M
FCF MarginFCF / Revenue
-118.1%
-14.4%
Capex IntensityCapex / Revenue
4.5%
3.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$-16.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
LVO
LVO
Q4 25
$-2.3M
Q3 25
$-22.2M
$-3.2M
Q2 25
$-20.7M
$-3.0M
Q1 25
$-30.3M
$-4.3M
Q4 24
$3.5M
Q3 24
$-27.9M
$5.8M
Q2 24
$-39.0M
$1.3M
Q1 24
$-62.5M
$3.0M
Free Cash Flow
LAB
LAB
LVO
LVO
Q4 25
$-2.9M
Q3 25
$-23.1M
$-4.0M
Q2 25
$-22.6M
$-4.1M
Q1 25
$-35.3M
$-5.2M
Q4 24
$2.7M
Q3 24
$-30.1M
$5.2M
Q2 24
$-41.0M
$606.0K
Q1 24
$-63.3M
$2.1M
FCF Margin
LAB
LAB
LVO
LVO
Q4 25
-14.4%
Q3 25
-118.1%
-21.5%
Q2 25
-103.6%
-21.2%
Q1 25
-86.6%
-26.9%
Q4 24
9.2%
Q3 24
-136.4%
15.9%
Q2 24
-182.2%
1.8%
Q1 24
-138.9%
6.8%
Capex Intensity
LAB
LAB
LVO
LVO
Q4 25
3.2%
Q3 25
4.5%
4.4%
Q2 25
8.7%
5.3%
Q1 25
12.4%
4.8%
Q4 24
2.7%
Q3 24
10.2%
1.8%
Q2 24
8.6%
2.2%
Q1 24
1.7%
3.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

LVO
LVO

Advertising$15.8M78%
Membership Services$2.9M14%
Merchandising Revenue$1.6M8%

Related Comparisons